Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A multi-agent chemotherapy regimen combining eight different antineoplastic agents. This combination includes alkylating agents (cyclophosphamide, thiotepa), anthracyclines (doxorubicin), antimetabolites (fluorouracil, methotrexate), vinca alkaloids (vinblastine, vincristine), and a corticosteroid (prednisone). This comprehensive approach targets cancer cells through multiple mechanisms of action simultaneously, potentially improving efficacy in treating breast cancer, particularly in patients with node-positive disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclophosphamide + doxorubicin + fluorouracil + methotrexate + prednisone + thiotepa + vinblastine + vincristine.